Giuditta Illuzzi

This study shows that osimertinib treatment leads to a Drug Tolerant Persister state with replication defects, genome instability, and hypersensitivity to DNA repair inhibitors.

This study shows that combining androgen receptor inhibitors with PARP inhibitors enhances DNA damage in prostate cancer models, independent of BRCA mutations, by increasing double-strand breaks and micronuclei formation.